296.44
0.53 (0.18%)
| 前收盘价格 | 295.91 |
| 收盘价格 | 295.95 |
| 成交量 | 168,432 |
| 平均成交量 (3个月) | 1,195,433 |
| 市值 | 39,578,468,352 |
| 市盈率 (P/E TTM) | 74.30 |
| 预期市盈率 (P/E Forward) | 31.65 |
| 价格/销量 (P/S) | 9.42 |
| 股市价格/股市净资产 (P/B) | 36.63 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2026 |
| 营业毛利率 | -11.49% |
| 营业利益率 (TTM) | 3.04% |
| 稀释每股收益 (EPS TTM) | -2.11 |
| 季度收入增长率 (YOY) | 20.20% |
| 总债务/股东权益 (D/E MRQ) | 2,358.25% |
| 流动比率 (MRQ) | 3.04 |
| 营业现金流 (OCF TTM) | -45.11 M |
| 杠杆自由现金流 (LFCF TTM) | 223.09 M |
| 资产报酬率 (ROA TTM) | -1.79% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Alnylam Pharmaceuticals, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 1.38 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Core |
| 内部持股比例 | 3.81% |
| 机构持股比例 | 97.56% |
| 52周波幅 | ||
| 中 | 510.00 (72.04%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 18 Feb 2026 | 510.00 (72.04%) | 购买 | 332.68 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合